Hot Features
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopa... Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.01 | -1.75438596491 | 0.57 | 0.57 | 0.56 | 100 | 0.57 | CS |
| 4 | -0.02 | -3.44827586207 | 0.58 | 0.6 | 0.54 | 10011 | 0.57025746 | CS |
| 12 | -0.05 | -8.19672131148 | 0.61 | 0.64 | 0.51 | 17301 | 0.56663409 | CS |
| 26 | -0.04 | -6.66666666667 | 0.6 | 0.65 | 0.44 | 19142 | 0.5543084 | CS |
| 52 | -0.25 | -30.8641975309 | 0.81 | 0.87 | 0.44 | 20533 | 0.64451976 | CS |
| 156 | -0.08 | -12.5 | 0.64 | 1.06 | 0.44 | 20001 | 0.68824723 | CS |
| 260 | 0.16 | 40 | 0.4 | 1.06 | 0.375 | 19098 | 0.65862521 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.